Head to Head Contrast: Polyrizon (NASDAQ:PLRZ) vs. Molecular Partners (NASDAQ:MOLN)

Molecular Partners (NASDAQ:MOLN) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Volatility & Risk

Molecular Partners has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Polyrizon has a beta of -4.6, meaning that its share price is 560% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Molecular Partners and Polyrizon, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1	1	2	0	2.25
Polyrizon	1	0	0	0	1.00

Molecular Partners currently has a consensus price target of $8.38, suggesting a potential upside of 99.40%. Given Molecular Partners’ stronger consensus rating and higher possible upside, analysts plainly believe Molecular Partners is more favorable than Polyrizon.

Valuation and Earnings

This table compares Molecular Partners and Polyrizon”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65 million	30.02	-$74.41 million	($1.99)	-2.11
Polyrizon	N/A	N/A	-$3.34 million	N/A	N/A

Polyrizon has lower revenue, but higher earnings than Molecular Partners.

Profitability

This table compares Molecular Partners and Polyrizon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-60.62%	-51.84%
Polyrizon	N/A	N/A	N/A

Institutional & Insider Ownership

26.6% of Molecular Partners shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Molecular Partners beats Polyrizon on 7 of the 10 factors compared between the two stocks.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.